

Arch Capital

Momentum in MI and Reinsurance Drove Healthy Results

Arch's results exceeded expectations, as upside in the reinsurance and mortgage insurance business offset a shortfall in insurance. We maintain an upbeat long-term outlook for ACGL, but are Neutral on the stock due to concerns about downside risk to consensus EPS estimates and current valuation.

- EPS upside; cutting 1Q25 forecasts for LA fires, maintaining 2Q25 and beyond.** ACGL announced 4Q24 operating EPS of \$2.26, above our \$1.85 estimate and consensus of \$1.80. Compared with our model, part of the beat was due to lower cat losses (+\$0.10 per share variance after taxes), more favorable P&C development (+\$0.02), and a lower tax rate (+\$0.07), but earnings would have exceeded estimates even adjusted for these items, which tend to fluctuate on a quarterly basis. We are cutting our 1Q25 EPS estimates from \$2.41 to \$1.52, but are maintaining our forecasts for future periods.
- Business fundamentals were strong overall, except in the insurance division.** Mortgage insurance margins were robust (CR 13.4% versus our 17.9% assumption), helped by reserve releases, consistent with the trend in recent periods. Reinsurance margins were strong as well (CR 83.0% vs. 91.3%E), marked by lower attritional and cat losses. Conversely, insurance division margins were pressured by an uptick in attritional and cat losses, which drove weaker margins on both a reported basis (CR 98.5% vs. 93.1%E) and core (CR ex. cats and PYD 90.3% vs. 89.0%E). Insurance division reserve development was positive, but less so than in previous periods. However, management indicated that there were no major shifts in casualty reserves. Arch deployed \$24 million for share repurchases in the quarter (our model assumed none) and management could continue buybacks if the stock stays close to the current level.
- Our model projects ACGL to report strong results in the near term, but our long-term view of the reinsurance market is mixed.** We forecast Arch to report strong underwriting margins, and healthy top-line growth in its reinsurance and insurance businesses. Reinsurance margins should benefit from elevated reinsurance prices and favorable terms (higher attachment points, lack of aggregate covers). In mortgage insurance, top-line growth is likely to be weak, but we expect high home prices and the strong labor market to drive robust margins. On the other hand, despite our near-term optimism, we do not project margins in the reinsurance or MI businesses to sustain at recent levels in the long run.
- We reiterate our Neutral rating.** In our view, Arch is a top-tier franchise, but in commoditized markets. Near term, tight reinsurance terms and the favorable housing and labor market environment should drive strong results in both the reinsurance and MI businesses. Still, we do not expect the company's margins and ROE to sustain at recent levels in the long run. The stock's valuation seems more reasonable following the pullback in late 2024, but it is still not too enticing given ACGL's long-term ROE and EPS growth potential.

Sources for: Style Exposure – J.P. Morgan Quantitative and Derivatives Strategy; all other tables are company data and J.P. Morgan estimates.

Neutral

ACGL, ACGL US
Price (10 Feb 25): \$91.46
Price Target (Dec-25): \$106.00

Insurance - Life & Nonlife

Jimmy S. Bhullar, CFA^{AC}

(1-212) 622-6397
jimmy.s.bhullar@jpmorgan.com

Pablo S. Singzon

(1-212) 622-2295
pablo.s.singzon@jpmorgan.com

Kevin Wijendra

(1-212) 622-7054
kevin.wijendra@jpmorgan.com

Judson Lindley

(1-212) 622-1712
judson.lindley@jpmorgan.com
J.P. Morgan Securities LLC

Key Changes (FYE Dec)

	Prev	Cur
Adj. EPS - 25E (\$)	8.69	7.80

Quarterly Forecasts (FYE Dec)

Adj. EPS (\$)	2024A	2025E	2026E
Q1	2.45	1.52	
Q2	2.57	2.19	
Q3	1.99	1.87	
Q4	2.26	2.22	
FY	9.28	7.80	9.30

Style Exposure

Quant Factors	Current		Hist %Rank (1=Top)			
	%Rank	6M	1Y	3Y	5Y	
Value	100	100	100	100	100	100
Growth	1	1	100	1	1	1
Momentum	51	1	1	1	1	51
Quality	51	51	1	1	1	1
Low Vol	1	1	1	51	51	1
ESGQ	12	12	14	90	90	97

4Q24 EPS: \$2.26A vs. \$1.85E

Positives: MI margins; reinsurance margins; insurance premiums

Negatives: insurance margins

See page 14 for analyst certification and important disclosures.

J.P. Morgan does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision.

Price Performance



Company Data

Shares O/S (mn)	376
52-week range (\$)	110.75-78.69
Market cap (\$ mn)	34,425.54
Exchange rate	1.00
Free float (%)	94.4%
3M ADV (mn)	1.89
3M ADV (\$ mn)	179.5
Volatility (90 Day)	29
Index	S&P 500
BBG ANR (Buy Hold Sell)	12 4 1


Key Metrics (FYE Dec)

	FY24A	FY25E	FY26E
Financial Estimates			
NEP (Premium)	15,100	16,362	17,523
Underwriting income	2,661	2,369	2,393
Net investment income	1,495	1,803	2,045
Operating income	4,156	4,172	4,438
Adj. PBT	4,674	4,454	4,746
Adj. net income	3,542	3,235	3,458
Adj. EPS	9.28	7.80	9.30
BBG EPS	8.84	8.92	9.60
DPS	5.00	3.00	0.00
Investments	18,639	21,245	24,239
BVPS	53.11	59.47	68.49
NAVPS	53.11	59.47	68.49
Margins and Growth			
Adj. EPS growth	9.8%	(15.9%)	19.2%
Ratios			
Adj. tax rate	7.7%	15.0%	15.0%
Loss ratio	(55.2%)	(57.3%)	(58.3%)
Combined ratio	(28.1%)	(29.1%)	(30.2%)
Invest inc. % of Investments	-	-	-
Regulatory solvency ratio	-	-	-
Leverage (Debt/Debt+Equity)	-	-	-
ROE	18.9%	15.2%	14.4%
Valuation			
Dividend yield	5.5%	3.3%	0.0%
Adj. P/E	9.9	11.7	9.8
P/BV	1.7	1.5	1.3

Summary Investment Thesis and Valuation

We affirm our Neutral rating. Arch is a leading commercial re/insurance underwriter that should produce superior and less volatile underwriting margins compared to peers. In reinsurance, near-term results should benefit from the firm pricing environment and tight terms/conditions. Margins in the MI business should remain healthy in the near-term as well, but we expect the benefit from reserve releases to moderate compared to recent years. Meanwhile, our long-term outlook for the reinsurance market remains cautious, and we expect pricing to deteriorate further if margins remain close to recent levels. This, along with optimistic investor sentiment and concerns about downside risk to consensus estimates keep us Neutral on ACGL.

Performance Drivers



Factors	6M Corr	1Y Corr
Market: MSCI EM Latam	0.12	0.14
Country: Bermuda	0.04	-0.02
Macro:		
JPM Forecast Revision EM	-0.43	-0.33
JPM Global Equity Sentiment	0.18	0.23
Markit EM Composite PMI SA	-0.32	-0.20
Quant Styles:		
Value	0.26	0.31
LowVol	0.04	0.14
DivYld	0.06	0.13

Table Of Contents

Investment Thesis	4
P&C Reinsurance: Near-Term View Positive; L-T Cautious.....	4
MI: Margins to Normalize Lower, Growth Weak.....	4
4Q24 Details	5
Mortgage Ins.: Margins Strong, Gross Premium Growth Weak	6
Insurance: Higher Cats and AY Loss Picks Drove Miss.....	8
Reinsurance: Robust Margins Lifted Earnings.....	9
Cutting 1Q25 EPS Estimate	11

Investment Thesis

Please see Page 5 for a detailed review of 4Q24 results. ACGL will hold its earnings conference call at 11:00 AM Eastern on February, 11, 2025. Conference call participants need to register at this link: events.q4inc.com/attendee/117379889/guest. The call replay can be accessed at: ir.archcapgroup.com.

We are Neutral on Arch, but our overall view is relatively upbeat and we consider it an attractive stock for those seeking exposure to the firm reinsurance market. Arch is a premier re/insurance underwriter with a unique culture and approach to risk management that should generate superior, and less volatile, margins over time. The company also has a leading mortgage insurance franchise, a business that we view as structurally superior to P&C reinsurance. In primary P&C, Arch has expanded its position in wholesale/E&S through the current hard market and the acquisition of MidCorp should add scale and distribution to its middle market franchise. Our near term outlook for Arch is positive, and we forecast its results to benefit from tight terms/conditions in the reinsurance market as well as continued reserve releases in mortgage insurance. However, our longer term outlook is more muted, and we expect reinsurance prices to soften over the next 1-2 years if underwriting margins remain close to recent levels. The reinsurance market is plagued by structural issues such as low barriers to entry, lack of differentiation among carriers, and limited pricing power, all of which suggest greater competition if margins remain near recent levels. Also, investor sentiment on ACGL is bullish, and we feel that the stock's valuation is not particularly enticing. Still, our fundamental outlook for the company remains constructive and we could become more bullish if the stock pulls back.

P&C Reinsurance: Near-Term View Positive; L-T Cautious

Our model projects disciplined pricing and terms to drive robust margins in the reinsurance business over the next year. ACGL has historically generated better and less volatile margins than reinsurance peers due to its focus on specialty business (where pricing is less competitive), conservative underwriting, ability to shift mix with changing conditions, and judicious management of catastrophe risk. Also, ACGL prices business using the risk-free rate (leading to conservative pricing), incentivizes underwriters with a long-term compensation plan based on margins over multiple years, and diversifies re/insurance underwriting income with fees from 3rd party capital vehicles such as Premia. **Still, we are cautious on long-term trends in the reinsurance market** because of its commoditized nature, the ease of entry of new capital, and a broad set of capital providers (including some, such as pension funds, with lower return thresholds). We are skeptical of a prolonged hard market and feel that strong margins in recent years will likely erode pricing discipline. As such, we expect a softening of pricing and terms over the next 1-2 years, especially in higher reinsurance layers, where more capital is forming. Any signs of softening of terms/conditions or new capacity will likely hurt sentiment on reinsurance stocks, which are well-liked.

MI: Margins to Normalize Lower, Growth Weak

ACGL expanded its position in mortgage insurance via acquisitions (CMG in 2014 and United Guaranty in 2016) when market conditions were favorable, marked by rising home prices, tight lending standards, and disciplined pricing by MI carriers. Arch's MI business has reported healthy margins since then and, despite the temporary setback from COVID-related delinquencies in 2020, results have been strong. We expect MI margins to be strong in the near-term, but normalize over time as reserve releases moderate. Results in the next few quarters should benefit from ACGL's conservative loss picks post-COVID, the strong labor market, and the increase in house prices. Meanwhile, higher rates are likely to continue suppressing new sales.

4Q24 Details

This evening, Arch announced fourth quarter 2024 operating EPS of \$2.26, above our \$1.85 estimate and consensus of \$1.80. Part of the upside to our model was driven by lower cat losses (+\$0.10 per share variance after taxes), more favorable P&C development (+\$0.02), and a lower tax rate (+\$0.07). Still, earnings would have exceeded estimates even adjusted for these items, which tend to fluctuate on a quarterly basis, as strong results in the mortgage insurance and reinsurance divisions offset a shortfall in insurance.

Table 1: 4Q24 Operating Earnings: Actual versus Expected

\$ in millions, except per share amounts

	4Q24E	4Q24A	Upside / (downside) to EPS	Comments
Underwriting Income by Division:				
Mortgage	227	267	\$0.11	net written premiums +8.6% vs. +9.2%E; combined ratio 13.4% vs. 17.9%E
Insurance	113	30	-\$0.22	net written premiums +34.9% vs. +26.8%E; combined ratio 98.4% vs. 93.1%E
Reinsurance	168	328	\$0.42	net written premiums +2.0% vs. +25.1%E; combined ratio 83.0% vs. 91.3%E
Underwriting income	508	625	\$0.31	net written premiums +17.1% vs. +24.6%E; combined ratio 85.1% vs. 86.9%E
Net investment income	420	405	-\$0.04	pre-tax investment yield of 4.32% in 4Q24 versus 4.40% in 3Q24 and 4.11% in 4Q23
Earnings from affiliates	35	64	\$0.08	
Other income (losses) / COLI	1	38	\$0.10	
Other expenses / corporate	132	156	-\$0.06	
Interest expense	35	37	\$0.00	
Pretax operating income	796	939	\$0.37	
Income tax expense	80	63	\$0.04	tax rate of 6.7% vs. 10.0%E
Preferred dividends	10	10	\$0.00	
Operating income	707	866	\$0.42	
Weighted average dilutive shares	382.7	382.8	\$0.00	buybacks of \$24 million versus our assumption of no repurchases
Operating EPS	\$1.85	\$2.26	\$0.42	no major unusual items

Source: Company reports and J.P. Morgan estimates.

Business fundamentals were healthy overall. Mortgage insurance margins were robust (CR 13.4% versus our 17.9% assumption), helped by reserve releases, consistent with the trend in recent periods. Reinsurance margins were strong as well (CR 83.0% vs. 91.3%E), marked by lower attritional and cat losses. Conversely, insurance division margins were pressured by an uptick in attritional and cat losses, which drove weaker margins on both a reported basis (CR 98.5% vs. 93.1%E) and core (CR ex. cats and PYD 90.3% vs. 89.0%E). Arch deployed \$24 million for share repurchases in the quarter (our model assumed none).

Table 2: 4Q24 Key Financial Metrics

\$ in millions

	4Q24E	4Q24A
Net premiums earned	3,848	4,143
% change (y-o-y)	15.1%	23.9%
Net premiums written	4,064	3,819
% change (y-o-y)	24.6%	17.1%
Net investment income	420	405
% change (y-o-y)	34.1%	29.4%
Loss ratio ex cats and PYD	52.6%	51.6%
Catastrophe losses	10.5%	9.5%
PYD (favorable) / unfavorable	-3.3%	-3.5%
Loss ratio	59.7%	57.5%
Expense ratio	27.2%	27.5%
Combined ratio	86.9%	85.1%
Combined ratio ex cats & PYD	79.7%	79.1%
Share buybacks (\$ mil.)	-	24

Source: Company reports and J.P. Morgan estimates.

Mortgage Ins.: Margins Strong, Gross Premium Growth Weak

We expect mortgage insurance (MI) premiums to decline at a low-single-digit pace and margins to gradually compress as reserve releases moderate. Although the absolute level of MI earnings should stay healthy, we project margins to decline as reserve releases moderate. Also, higher interest rates are likely to continue to weigh on new business. On a positive note, the cancellation of the Bellemeade transactions and higher interest rates should boost retention, partially offsetting lower sales.

In 4Q24, the MI business posted underwriting income of \$267 million, well above our \$227 million estimate, due to better margins (CR 13.4% vs. 17.9%E) and higher earned premium growth (+11.3% vs. -0.5%E). Most of the upside in margins was driven by lower attritional claims (16.4% vs. 23.0%E) as reserve releases were only modestly better than expected (-22.3% vs. -22.0%E) and the expense ratio was worse (19.3% vs. 16.9%E). Management attributed the reserve releases to better than expected cure rates and the higher expense ratio to lower ceding commissions as well as the costs of a one-time voluntary separation program. Gross premiums were weak (13th consecutive quarter of decline), but net written and net earned premium growth benefited from the termination of the Bellemeade agreements in 4Q23. Overall, we expect the positive drivers of MI margins (higher interest rates, lower inventory of houses, etc.) to suppress gross premium growth through 2025.

During COVID (2020 and early 2021), MI margins were hurt by artificially high delinquencies as homeowners took advantage of government forbearance programs. However, since the initial spike in 2Q20, the number of delinquent loans has been steadily declining. Since the expiry of forbearance programs, a significant portion of previously delinquent loans have cured, particularly loans by borrowers who were taking advantage of the mortgage payment holiday but were not in financial distress. In addition, rising house prices have provided a cushion to homeowners under stress who are struggling to pay their mortgages, limiting losses for MI carriers. The percent of loans in default in the U.S. primary MI business was 2.09% at 12/31/2024, up from 1.96% at 9/30/2024 and 1.74% at 12/31/23.

Table 3: Mortgage Insurance Key Metrics

\$ in millions

	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24	3Q24	4Q24E	4Q24A
Net written premiums	275	1,133	261	265	271	255	1,052	277	276	282	278	277
Premium Growth (y/y)	-5.1%	-10.2%	-9.4%	-9.8%	-1.9%	-7.1%	-7.1%	6.1%	4.2%	4.1%	9.2%	8.6%
Losses and LAE ex. cats and PYD	25.2%	20.7%	25.3%	24.3%	21.6%	18.3%	22.4%	22.7%	20.2%	22.5%	23.0%	16.4%
Catastrophe losses	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
PYD (favorable) / unfavorable	-72.1%	-48.6%	-24.6%	-28.7%	-33.5%	-39.0%	-31.3%	-25.7%	-29.0%	-22.8%	-22.0%	-22.3%
Loss ratio	-46.9%	-28.0%	0.7%	-4.4%	-11.9%	-20.7%	-8.9%	-3.0%	-8.8%	-0.3%	1.0%	-5.9%
Acquisition expense ratio	4.4%	3.5%	2.4%	2.4%	0.7%	0.4%	1.5%	0.0%	0.0%	-0.3%	0.4%	1.0%
Operating expense ratio	15.4%	16.8%	16.9%	17.0%	16.0%	17.1%	16.8%	17.4%	16.0%	15.7%	16.5%	18.3%
Expense ratio	19.8%	20.3%	19.3%	19.4%	16.7%	17.5%	18.2%	17.4%	16.0%	15.3%	16.9%	19.3%
Combined ratio	-27.1%	-7.7%	19.9%	15.0%	4.8%	-3.3%	9.3%	14.4%	7.2%	15.0%	17.9%	13.4%
Combined ratio ex cats & PYD	45.0%	41.0%	44.5%	43.7%	38.3%	35.7%	40.6%	40.1%	36.2%	37.8%	39.9%	35.7%
Underwriting Income (Loss)	374	1,257	243	253	282	286	1,064	271	287	269	227	267

Source: Company reports and J.P. Morgan estimates.

In our view, reserve releases will continue to lift MI margins, but the tailwind should moderate over time. Higher reported delinquencies at the onset of COVID led Arch and its MI peers to establish conservative reserves despite the healthy labor market and appreciation in house prices. A significant portion of these delinquencies represented homeowners availing themselves of the government's forbearance protection programs (to preserve liquidity), not actual financial hardship. As such, actual losses have come in well below those suggested by initial delinquencies, allowing ACGL to release reserves. In recent quarters, the vast majority of MI reserve releases have been from post-COVID accident years. Even with likely moderation, however, we forecast MI margins to remain robust due to the strong labor and housing markets, cures on previously delinquent loans, and the equity cushion accumulated by homeowners due to the appreciation in house prices. Higher interest rates are a positive for margins as well, as they are causing homeowners to stay longer in their existing houses (where they have more equity), thereby improving persistency. Meanwhile, top-line growth in the MI business is likely to stay weak as higher interest rates reduce mortgage originations. Although a weaker economy could deflate home prices and lead to higher mortgage defaults, a material uptick in losses seems unlikely in the near term. Barring a recession, we expect core margins to stay healthy, though declining reserve releases will drive margins and earnings lower even if economic trends remain favorable.

ACGL has been an active acquirer of MI businesses in the past, but we do not anticipate deals in the near term. Arch has become a leading franchise in the mortgage re/insurance since its entry to the market in 2011. The company was only marginally involved in the market at the onset, competing as a primary insurer through credit unions and as a reinsurer through the GSE credit risk transfer program. ACGL's 2014 acquisition of CMG Mortgage Insurance from Cuna Mutual gave it a bigger foothold as it received a ratings upgrade for its MI business (from BBB+ to A- at S&P) and gained distribution in the bank channel. Following the deal, ACGL became a top 10 competitor in the domestic private MI market. Arch further solidified its market position with its 2017 acquisition of United Guaranty (UGC) from AIG, which moved it into the top-3 by market share (as part of the deal AIG retained 50% of mortgage insurance blocks originated by UGC pre 2017). Arch has also expanded in foreign MI markets through M&A, including its acquisition of Westpac's mortgage insurance business in Australia (closed in August 2021).

Insurance: Higher Cats and AY Loss Picks Drove Miss

The insurance business reported weak results, marked by a shortfall in margins but strong premium growth. The insurance division reported underwriting income of \$30 million in 4Q24, well short our \$113 million estimate. Margins were worse than our estimates on both a reported (CR 98.5% vs. 93.1%E) and a core basis (CR ex. cats and PYD 90.3% vs. 89.0%E). The loss ratio increased (66.3% vs. 61.1%E) due to higher catastrophe losses (8.3% vs. 4.5%E) and attritional losses (58.1% vs. 57.0%E) as well as lower reserve releases (-0.1% vs. -0.4%E). Also, expenses were slightly higher than assumed as well (32.2% vs. 32.0%E). Moreover, catastrophe losses in the primary insurance division were high, which the company attributed partly to inland flooding caused by Helene as well as the addition of the MidCorp book. Meanwhile, top-line growth was better, with upside in gross written premium growth (+28.4% vs. +23.4%E), net written premium growth (+34.9% vs. +26.8%E), and net earned premium growth (+33.4% vs. +13.3%E). Besides the addition of the MidCorp business, management cited growth in short-tail and liability-occurrence lines as drivers of premium growth.

Management called out the addition of the MidCorp portfolio, increases in accident year loss picks, and a shift in business mix towards casualty as the drivers of the higher loss ratio. The expense ratio benefited by 2.9 points from acquisition accounting (acquisition expense on the MidCorp block, a component of the expense ratio, was replaced with purchase intangibles, the amortization of which is reflected in the consolidated income statement, but not in the combined ratio).

Table 4: Insurance Key Metrics

\$ in millions

	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24	3Q24	4Q24E	4Q24A
Net written premiums	1,217	5,021	1,437	1,454	1,522	1,449	5,862	1,542	1,558	1,820	1,837	1,954
Premium Growth (y/y)	17.4%	21.0%	19.1%	18.4%	11.2%	19.1%	16.8%	7.3%	7.2%	19.6%	26.8%	34.9%
Losses and LAE ex. cats and PYD	56.2%	56.0%	54.8%	55.2%	55.7%	55.1%	55.2%	57.5%	55.6%	57.4%	57.0%	58.1%
Catastrophe losses	2.8%	5.3%	1.6%	2.6%	2.6%	3.8%	2.7%	1.9%	2.0%	4.9%	4.5%	8.3%
PYD (favorable) / unfavorable	-0.3%	-0.2%	-0.5%	-0.5%	-0.8%	-0.5%	-0.6%	-0.5%	-0.2%	-0.7%	-0.4%	-0.1%
Loss ratio	58.7%	61.0%	55.9%	57.3%	57.5%	58.4%	57.3%	58.9%	57.4%	61.6%	61.1%	66.3%
Acquisition expense ratio	19.6%	19.4%	19.5%	19.9%	19.1%	19.1%	19.4%	19.0%	19.5%	17.5%	17.7%	17.8%
Operating expense ratio	13.8%	14.6%	15.5%	14.7%	14.3%	15.7%	15.0%	16.2%	15.8%	14.2%	14.3%	14.3%
Expense ratio	33.5%	34.0%	35.0%	34.6%	33.4%	34.8%	34.4%	35.2%	35.3%	31.6%	32.0%	32.2%
Combined ratio	92.1%	95.1%	90.9%	91.9%	90.9%	93.2%	91.7%	94.1%	92.6%	93.2%	93.1%	98.4%
Combined ratio ex cats & PYD	89.6%	90.0%	89.8%	89.8%	89.1%	89.9%	89.6%	92.7%	90.8%	89.0%	89.0%	90.2%
Underwriting Income (Loss)	98	225	114	108	129	99	450	86	109	120	113	30

Source: Company reports and J.P. Morgan estimates.

Arch's primary P&C business is benefiting from healthy commercial lines pricing, but we believe margins are likely to deteriorate in the near term. After shrinking its “cycle managed” business (now called wholesale/large capacity) from 2012 to 2017, ACGL is deploying capital in this part of its primary book due to favorable conditions in the broader market, particularly in E&S. Results in less cyclical parts of ACGL’s primary business (specialty small/middle market and franchise) have been healthy as well. Despite the favorable market environment, we do not anticipate a material improvement in primary commercial lines margins at Arch and peers because of headwinds from adverse development of casualty reserves as well as higher inflation and reinsurance costs. Also, pricing has deteriorated in certain lines (particularly in property), and reserve development could become less of a tailwind because of adverse loss trends emerging in older accident years. Management teams at insurance underwriters as well as many investors are optimistic about improving non-cat margins at commercial insurers. However, we feel that assessing results on an underlying basis is not as relevant given the significant increase in reinsurance retentions at primary carriers. In our view, consensus EPS forecasts for commercial lines insurers do not fully reflect the shift in cat loads from reinsurers to primary carriers following the uptick in retention levels with 2023 reinsurance renewals.

Reinsurance: Robust Margins Lifted Earnings

ACGL’s reinsurance business reported robust results, as lower cat losses and more favorable PYD offset a modest shortfall in premiums. Underwriting income of \$328 million was well above our \$168 million estimate, primarily due to higher margins (CR 83.0% vs. 91.3%E). The upside in margins was driven by lower catastrophe losses (12.2% vs. 17.0%E) and, to a lesser extent, better reserve releases (-4.0% vs. -3.2%E). Underlying margins were better as well (CR ex. cats and PYD 74.8% vs. 77.5%E) due to upside in the attritional loss ratio (50.7% vs. 53.0%E) and expense ratio (24.1% vs. 24.5%E). Meanwhile, premium growth was below our assumption (gross written premiums -1.5% vs. +22.0%E, net written premiums +2.0% vs. 25.1%E, net earned premiums +17.5% vs. 19.3%E). The tightening of terms and conditions at 2023 renewals shifted the risk of cat losses from reinsurers to primary carriers, and

management indicated that terms remained consistent with 2025 renewals. Arch expects to incur losses of \$450-550 million related to the LA wildfires, assuming industry wide insured losses between \$35 and \$45 billion, and management believes that the likelihood of industry wide insured losses from the event reaching \$50 billion (as highlighted by some peers) is very low.

Table 5: Reinsurance Key Metrics

\$ in millions

	4Q22	2022	1Q23	2Q23	3Q23	4Q23	2023	1Q24	2Q24	3Q24	4Q24E	4Q24A
Net written premiums	1,543	4,924	1,726	1,709	1,562	1,557	6,554	2,266	1,947	1,945	1,948	1,588
Premium Growth (y/y)	117.6%	51.3%	51.5%	47.0%	44.8%	0.9%	33.1%	31.3%	13.9%	24.5%	25.1%	2.0%
Losses and LAE ex. cats and PYD	57.4%	56.2%	56.6%	50.8%	49.9%	48.5%	51.3%	53.7%	48.9%	52.2%	53.0%	50.7%
Catastrophe losses	0.0%	12.9%	4.4%	6.3%	9.3%	5.1%	6.3%	1.8%	9.4%	19.3%	17.0%	12.2%
PYD (favorable) / unfavorable	-4.5%	-4.3%	-3.4%	-1.8%	-2.8%	-1.3%	-2.3%	-2.5%	-1.8%	-1.9%	-3.2%	-4.0%
Loss ratio	52.9%	64.9%	57.6%	55.3%	56.4%	52.3%	55.3%	53.0%	56.5%	69.6%	66.8%	58.9%
Acquisition expense ratio	19.9%	20.5%	21.1%	21.6%	19.7%	22.5%	21.2%	19.9%	19.4%	19.8%	20.5%	20.1%
Operating expense ratio	5.6%	6.8%	5.6%	5.1%	4.0%	5.2%	4.9%	4.5%	3.6%	2.9%	4.0%	4.0%
Expense ratio	25.5%	27.3%	26.7%	26.7%	23.7%	27.8%	26.2%	24.4%	23.0%	22.6%	24.5%	24.1%
Combined ratio	78.5%	92.2%	84.3%	82.0%	80.0%	80.1%	81.5%	77.4%	79.5%	92.2%	91.3%	83.0%
Combined ratio ex cats & PYD	83.0%	83.5%	83.3%	77.5%	73.5%	76.3%	77.4%	78.1%	71.9%	74.8%	77.5%	74.8%
Underwriting Income (Loss)	263	314	213	245	310	330	1,098	379	366	149	168	328

Source: Company reports and J.P. Morgan estimates.

We are skeptical of a prolonged hard reinsurance market, but recent catastrophes bode well for market discipline and ACGL seems better positioned than peers.

ACGL's reinsurance segment was initially established to take advantage of the hard market for casualty coverage in the early 2000s. Over the years, however, management has increased Arch Re's exposure to other specialty lines including surety, accident and health, agriculture, and trade credit, which are generally less competitive and have more attractive risk-reward. The hard pricing environment has boosted results in recent years and has led management to increase exposure to property coverages, which in turn has contributed to strong premium growth and margins. Longer term, however, we expect reinsurance pricing to deteriorate. Factors that contributed to a multi-year soft market prior to 2018 (glut of capital, greater fluidity/speed of capital, more providers of capacity, broker consolidation) are still prevalent, and should preclude prolonged hard pricing. On a positive note, ACGL's reinsurance results could benefit from the release of COVID-related reserves, a portion of which remain in IBNR. Similarly, loss reserves for Ian and other cat events could ultimately prove to be too conservative.

Cutting 1Q25 EPS Estimate

We are reducing our 1Q25 operating EPS estimates from \$2.41 to \$1.52 and our 2025 projection from \$8.69 to \$7.80, respectively, for the LA wildfires. Meanwhile, our projections for quarters beyond 1Q25 are unchanged. Our estimates for 2025 and beyond are below consensus levels, which we feel are optimistic. We consider catastrophe losses (which would affect reinsurance and insurance margins) and housing market conditions (which affect MI margins and premium growth) the key sources of potential upside or downside in reported results versus our projections.

Arch Capital (Neutral; Price Target: \$106.00)

Investment Thesis

Arch is a superior re/insurance underwriter, but bullish investor sentiment and optimistic consensus estimates keep us from being more constructive on the stock. In our view, ACGL's leading reinsurance business will report higher and less volatile underwriting margins over time given its unique culture and approach to underwriting. The reinsurance business should benefit from firm pricing and tight terms/conditions in the near term, but our long-term outlook for the market is downbeat. We believe that structural issues such as low barriers to entry, lack of differentiation by carrier, and limited pricing power will drive a softening of reinsurance prices over the next one to two years. Meanwhile, Arch is a top competitor in mortgage insurance (MI), which we believe is a structurally better business than P&C reinsurance. We expect MI results to be marked by strong margins in the near term, but we expect reserve releases to moderate from recent years and premium growth to remain weak. Also, investor sentiment on ACGL is bullish, and we believe that consensus EPS forecasts are too optimistic.

Valuation

We are maintaining our December 2025 price target of \$106. Our price target assumes a 1.8x multiple on our 12/31/25E BV ex. AOCI forecast, a 1.9x multiple on our 12/31/25E BV forecast, and an 11.0x multiple on our 2026 EPS estimate, and we corroborate this approach with a sum-of-the-parts analysis that values ACGL's re/insurance business separately from mortgage insurance. Our target multiples for ACGL reflect its current business mix, which has become less skewed to MI. ACGL trades at 1.7x BV and 11.7x 2025E EPS compared to 1.3x and 8.4x for the reinsurance sector, 1.1x and 8.4x for MI peers, and 1.9x and 12.4x for the broader P&C group.

Risks to Rating and Price Target

In our opinion, ACGL could outperform and exceed our price target if:

- **Re/insurance pricing stays firm for a prolonged period.** A prolonged hard market could drive upside to our EPS forecasts and boost sentiment on the stock.
- **Management sustains insurance underwriting margins close to the recent level.** We believe investor sentiment could improve if ACGL is able to sustain insurance combined ratios in the low-to-mid 90s, a significant improvement from ~100% previously, even as the tailwind from the current hard market abates.
- **Arch announces a sizable share repurchase program.** Steady repurchases by leading reinsurers could help prolong the hard market as well as drive an uptick in EPS forecasts.

We feel that the stock could underperform the group and fail to reach our target if:

- **Greater capacity enters the reinsurance market.** This, in turn, could result in further softening of pricing and drive a reduction in EPS estimates and hurt investor sentiment.
- **The housing market deteriorates.** Given Arch's meaningful exposure to mortgage insurance and the more systematic nature of mortgage insurance risk, rising unemployment, higher mortgage defaults, and decreasing home values would pressure the company's results and hurt sentiment on the stock.
- **The tailwind from reserve development moderates.** Favorable reserve development has been a notable contributor to ACGL's results in recent years. A slowdown in the pace of development could pressure margins and returns.

Arch Capital: Summary of Financials

Income Statement - Annual	FY24A	FY25E	FY26E	Income Statement - Quarterly	1Q25E	2Q25E	3Q25E	4Q25E
Earned premiums	-	-	-	Earned premiums	-	-	-	-
Policy charges and fee income	-	-	-	Policy charges and fee income	-	-	-	-
Net investment income	-	-	-	Net investment income	-	-	-	-
Other income	-	-	-	Other income	-	-	-	-
Total revenues	-	-	-	Total revenues	-	-	-	-
Insurance and annuity benefits	-	-	-	Insurance and annuity benefits	-	-	-	-
Interest credited	-	-	-	Interest credited	-	-	-	-
Interest expense	(141)	(152)	(158)	Interest expense	(37)	(38)	(38)	(39)
Acquisition & operating expenses	(2,651)	(3,024)	(3,245)	Acquisition & operating expenses	(724)	(744)	(777)	(779)
Amortization of acquisition costs (net)	-	-	-	Amortization of acquisition costs (net)	-	-	-	-
Other expenses	-	-	-	Other expenses	-	-	-	-
Total expenses	-	-	-	Total expenses	-	-	-	-
Pretax income	4,674	4,454	4,746	Pretax income	1,220	1,126	981	1,126
Income taxes	(362)	(668)	(712)	Income taxes	(183)	(169)	(147)	(169)
Total net income	4,272	3,746	3,994	Total net income	1,027	947	824	947
Total operating income	3,542	3,235	3,458	Total operating income	900	819	696	820
Weighted average diluted shares	382	415	372	Weighted average diluted shares	592	374	372	369
EPS - operating	9.28	7.80	9.30	EPS - operating	1.52	2.19	1.87	2.22
Balance Sheet and Capital Data	FY24A	FY25E	FY26E	Ratio Analysis	FY24A	FY25E	FY26E	FY27E
Shareholders' equity	-	-	-	EPS growth - operating	9.8%	(15.9%)	19.2%	-
Shareholders' equity ex. AOCI	-	-	-	Book value per share (ex. AOCI) growth	12.9%	11.5%	14.8%	-
Shares outstanding	376	380	374	Return on equity (ROE)	18.9%	15.2%	14.4%	-
				Return on equity (ex. AOCI)	-	-	-	-
Book value per share	53.11	59.47	68.49					
Book value per share (ex. AOCI)	55.02	61.37	70.42	Dividend payout ratio	44.7%	33.2%	0.0%	-
Capital for share repurchases	-	-	-	Total revenue growth	-	-	-	-
Capital for dividends	-	-	-	Total expense growth	-	-	-	-
Dividends	5.00	3.00	0.00	Tax rate	7.7%	15.0%	15.0%	-

Source: Company reports and J.P. Morgan estimates.
 Note: \$ in millions (except per-share data). Fiscal year ends Dec

Analyst Certification: The Research Analyst(s) denoted by an “AC” on the cover of this report certifies (or, where multiple Research Analysts are primarily responsible for this report, the Research Analyst denoted by an “AC” on the cover or within the document individually certifies, with respect to each security or issuer that the Research Analyst covers in this research) that: (1) all of the views expressed in this report accurately reflect the Research Analyst’s personal views about any and all of the subject securities or issuers; and (2) no part of any of the Research Analyst’s compensation was, is, or will be directly or indirectly related to the specific recommendations or views expressed by the Research Analyst(s) in this report. For all Korea-based Research Analysts listed on the front cover, if applicable, they also certify, as per KOFIA requirements, that the Research Analyst’s analysis was made in good faith and that the views reflect the Research Analyst’s own opinion, without undue influence or intervention.


All authors named within this report are Research Analysts who produce independent research unless otherwise specified. In Europe, Sector Specialists (Sales and Trading) may be shown on this report as contacts but are not authors of the report or part of the Research Department.

Important Disclosures

- **Market Maker:** J.P. Morgan Securities LLC makes a market in the securities of Arch Capital or related entities.
- **Market Maker/ Liquidity Provider:** J.P. Morgan is a market maker and/or liquidity provider in the financial instruments of/related to Arch Capital or related entities.
- **Client:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients: Arch Capital or related entities.
- **Client/Investment Banking:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as investment banking clients: Arch Capital or related entities.
- **Client/Non-Investment Banking, Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-investment-banking, securities-related: Arch Capital or related entities.
- **Client/Non-Securities-Related:** J.P. Morgan currently has, or had within the past 12 months, the following entity(ies) as clients, and the services provided were non-securities-related: Arch Capital or related entities.
- **Investment Banking Compensation Received:** J.P. Morgan has received in the past 12 months compensation for investment banking services from Arch Capital or related entities.
- **Potential Investment Banking Compensation:** J.P. Morgan expects to receive, or intends to seek, compensation for investment banking services in the next three months from Arch Capital or related entities.
- **Non-Investment Banking Compensation Received:** J.P. Morgan has received compensation in the past 12 months for products or services other than investment banking from Arch Capital or related entities.
- **Debt Position:** J.P. Morgan may hold a position in the debt securities of Arch Capital or related entities, if any.

Company-Specific Disclosures: Important disclosures, including price charts and credit opinion history tables, are available for compendium reports and all J.P. Morgan-covered companies, and certain non-covered companies, by visiting <https://www.jpmm.com/research/disclosures>, calling 1-800-477-0406, or e-mailing research.disclosure.inquiries@jpmorgan.com with your request.

Arch Capital (ACGL, ACGL US) Price Chart



Source: Bloomberg Finance L.P. and J.P. Morgan; price data adjusted for stock splits and dividends.
 Initiated coverage Dec 15, 2003. All share prices are as of market close on the previous business day.

Date	Rating	Price (\$)	Price Target (\$)
01-Apr-22	N	48.42	51
27-Apr-22	N	46.51	52
06-Jul-22	N	44.44	53
27-Jul-22	N	44.24	54
26-Oct-22	N	49.22	57
04-Jan-23	N	62.46	58
31-Mar-23	N	67.86	62
26-Apr-23	N	72.59	67
06-Jul-23	N	73.62	75
26-Jul-23	N	81.36	82
30-Oct-23	N	81.36	86
08-Jan-24	N	76.81	80
14-Feb-24	N	84.06	88
08-Apr-24	N	94.90	92
29-Apr-24	N	90.90	96
11-Jul-24	N	97.50	106
30-Jul-24	N	97.01	108
10-Oct-24	N	113.09	110
03-Jan-25	N	91.38	106

The chart(s) show J.P. Morgan's continuing coverage of the stocks; the current analysts may or may not have covered it over the entire period.
 J.P. Morgan ratings or designations: OW = Overweight, N= Neutral, UW = Underweight, NR = Not Rated

Explanation of Equity Research Ratings, Designations and Analyst(s) Coverage Universe:

J.P. Morgan uses the following rating system: Overweight (over the duration of the price target indicated in this report, we expect this stock will outperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); Neutral (over the duration of the price target indicated in this report, we expect this stock will perform in line with the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe); and Underweight (over the duration of the price target indicated in this report, we expect this stock will underperform the average total return of the stocks in the Research Analyst's, or the Research Analyst's team's, coverage universe. NR is Not Rated. In this case, J.P. Morgan has removed the rating and, if applicable, the price target, for this stock because of either a lack of a sufficient fundamental basis or for legal, regulatory or policy reasons. The previous rating and, if applicable, the price target, no longer should be relied upon. An NR designation is not a recommendation or a rating. In our Asia (ex-Australia and ex-India) and U.K. small- and mid-cap Equity Research, each stock's expected total return is compared to the expected total return of a benchmark country market index, not to those Research Analysts' coverage universe. If it does not appear in the Important Disclosures section of this report, the certifying Research Analyst's coverage universe can be found on J.P. Morgan's Research website, <https://www.jpmorganmarkets.com>.

Coverage Universe: Bhullar, Jimmy S: AFLAC, Inc. (AFL), Allstate (ALL), American International Group (AIG), Aon (AON), Arch Capital (ACGL), Brighthouse Financial (BHF), Chubb Ltd (CB), Corebridge Financial (CRBG), Equitable Holdings Inc (EQH), Globe Life Inc (GL), Hartford Financial Services (HIG), Lincoln National (LNC), Marsh & McLennan (MMC), MetLife, Inc. (MET), Principal Financial Group (PFG), Progressive (PGR), Prudential Financial (PRU), Reinsurance Group of America (RGA), RenaissanceRe (RNR), Ryan Specialty Group (RYAN), Travelers Cos (TRV), Unum Group (UNM), Voya Financial, Inc. (VOYA)

J.P. Morgan Equity Research Ratings Distribution, as of January 01, 2025

	Overweight (buy)	Neutral (hold)	Underweight (sell)
J.P. Morgan Global Equity Research Coverage*	50%	37%	13%
IB clients**	50%	48%	37%
JPMS Equity Research Coverage*	47%	40%	13%
IB clients**	73%	68%	52%

*Please note that the percentages may not add to 100% because of rounding.

**Percentage of subject companies within each of the "buy," "hold" and "sell" categories for which J.P. Morgan has provided investment banking services within the previous 12 months.

For purposes of FINRA ratings distribution rules only, our Overweight rating falls into a buy rating category; our Neutral rating falls into a hold rating category; and our Underweight rating falls into a sell rating category. Please note that stocks with an NR designation are not included in the table above. This information is current as of the end of the most recent calendar quarter.

Equity Valuation and Risks: For valuation methodology and risks associated with covered companies or price targets for covered companies, please see the most recent company-specific research report at <http://www.jpmorganmarkets.com>, contact the primary analyst or your J.P.

Morgan representative, or email research.disclosure.inquiries@jpmorgan.com. For material information about the proprietary models used, please see the Summary of Financials in company-specific research reports and the Company Tearsheets, which are available to download on the company pages of our client website, <http://www.jpmorganmarkets.com>. This report also sets out within it the material underlying assumptions used.

A history of J.P. Morgan investment recommendations disseminated during the preceding 12 months can be accessed on the Research & Commentary page of <http://www.jpmorganmarkets.com> where you can also search by analyst name, sector or financial instrument.

Analysts' Compensation: The research analysts responsible for the preparation of this report receive compensation based upon various factors, including the quality and accuracy of research, client feedback, competitive factors, and overall firm revenues.

Other Disclosures

J.P. Morgan is a marketing name for investment banking businesses of JPMorgan Chase & Co. and its subsidiaries and affiliates worldwide.

UK MIFID FICC research unbundling exemption: UK clients should refer to [UK MIFID Research Unbundling exemption](#) for details of J.P. Morgan's implementation of the FICC research exemption and guidance on relevant FICC research categorisation.

All research material made available to clients are simultaneously available on our client website, J.P. Morgan Markets, unless specifically permitted by relevant laws. Not all research content is redistributed, e-mailed or made available to third-party aggregators. For all research material available on a particular stock, please contact your sales representative.

Any long form nomenclature for references to China; Hong Kong; Taiwan; and Macau within this research material are Mainland China; Hong Kong SAR (China); Taiwan (China); and Macau SAR (China).

J.P. Morgan Research may, from time to time, write on issuers or securities targeted by economic or financial sanctions imposed or administered by the governmental authorities of the U.S., EU, UK or other relevant jurisdictions (Sanctioned Securities). Nothing in this report is intended to be read or construed as encouraging, facilitating, promoting or otherwise approving investment or dealing in such Sanctioned Securities. Clients should be aware of their own legal and compliance obligations when making investment decisions.

Any digital or crypto assets discussed in this research report are subject to a rapidly changing regulatory landscape. For relevant regulatory advisories on crypto assets, including bitcoin and ether, please see <https://www.jpmorgan.com/disclosures/cryptoasset-disclosure>.

The author(s) of this research report may not be licensed to carry on regulated activities in your jurisdiction and, if not licensed, do not hold themselves out as being able to do so.

Exchange-Traded Funds (ETFs): J.P. Morgan Securities LLC (“JPMS”) acts as authorized participant for substantially all U.S.-listed ETFs. To the extent that any ETFs are mentioned in this report, JPMS may earn commissions and transaction-based compensation in connection with the distribution of those ETF shares and may earn fees for performing other trade-related services, such as securities lending to short sellers of the ETF shares. JPMS may also perform services for the ETFs themselves, including acting as a broker or dealer to the ETFs. In addition, affiliates of JPMS may perform services for the ETFs, including trust, custodial, administration, lending, index calculation and/or maintenance and other services.

Options and Futures related research: If the information contained herein regards options- or futures-related research, such information is available only to persons who have received the proper options or futures risk disclosure documents. Please contact your J.P. Morgan Representative or visit <https://www.theocc.com/components/docs/riskstoc.pdf> for a copy of the Option Clearing Corporation's Characteristics and Risks of Standardized Options or http://www.finra.org/sites/default/files/Security_Futures_Risk_Disclosure_Statement_2018.pdf for a copy of the Security Futures Risk Disclosure Statement.

Changes to Interbank Offered Rates (IBORs) and other benchmark rates: Certain interest rate benchmarks are, or may in the future become, subject to ongoing international, national and other regulatory guidance, reform and proposals for reform. For more information, please consult: https://www.jpmorgan.com/global/disclosures/interbank_offered_rates

Private Bank Clients: Where you are receiving research as a client of the private banking businesses offered by JPMorgan Chase & Co. and its subsidiaries (“J.P. Morgan Private Bank”), research is provided to you by J.P. Morgan Private Bank and not by any other division of J.P. Morgan, including, but not limited to, the J.P. Morgan Corporate and Investment Bank and its Global Research division.

Legal entity responsible for the production and distribution of research: The legal entity identified below the name of the Reg AC Research Analyst who authored this material is the legal entity responsible for the production of this research. Where multiple Reg AC Research Analysts authored this material with different legal entities identified below their names, these legal entities are jointly responsible for the production of this research. Research Analysts from various J.P. Morgan affiliates may have contributed to the production of this material but may not be licensed to carry out regulated activities in your jurisdiction (and do not hold themselves out as being able to do so). Unless otherwise stated below, this material has been distributed by the legal entity responsible for production. If you have any queries, please contact the relevant Research Analyst in your jurisdiction or the entity in your jurisdiction that has distributed this research material.

Legal Entities Disclosures and Country-/Region-Specific Disclosures:

Argentina: JPMorgan Chase Bank N.A Sucursal Buenos Aires is regulated by Banco Central de la República Argentina (“BCRA”- Central Bank of Argentina) and Comisión Nacional de Valores (“CNV”- Argentinian Securities Commission - ALYC y AN Integral N°51). **Australia:** J.P. Morgan Securities Australia Limited (“JPMSAL”) (ABN 61 003 245 234/AFS Licence No: 238066) is regulated by the Australian Securities and Investments Commission and is a Market Participant of ASX Limited, a Clearing and Settlement Participant of ASX Clear Pty Limited and a Clearing Participant of ASX Clear (Futures) Pty Limited. This material is issued and distributed in Australia by or on behalf of JPMSAL only to “wholesale clients” (as defined in section 761G of the Corporations Act 2001). A list of all financial products covered can be found by visiting <https://www.jpm.com/research/disclosures>. J.P. Morgan seeks to cover companies of relevance to the domestic and international investor base across all Global Industry Classification Standard (GICS) sectors, as well as across a range of market capitalisation sizes. If applicable, in the course of conducting public side due diligence on the subject company(ies), the Research Analyst team may at times perform such diligence through corporate engagements such as site visits, discussions with company representatives, management presentations, etc. Research issued by JPMSAL has been prepared in accordance with J.P. Morgan Australia’s Research Independence Policy which can be found at the following link: [J.P. Morgan Australia - Research Independence Policy](#). **Brazil:** Banco J.P. Morgan S.A. is regulated by the Comissão de Valores Mobiliários (CVM) and by the Central Bank of Brazil. Ombudsman J.P. Morgan: 0800-7700847 / 0800-7700810 (For Hearing Impaired) / ouvidoria.jp.morgan@jpmorgan.com. **Canada:** J.P. Morgan Securities Canada Inc. is a registered investment dealer, regulated by the Canadian Investment Regulatory Organization and the Ontario Securities Commission and is the participating member on Canadian exchanges. This material is distributed in Canada by or on behalf of J.P. Morgan Securities Canada Inc. **Chile:** Inversiones J.P. Morgan Limitada is an unregulated entity incorporated in Chile. **China:** J.P. Morgan Securities (China) Company Limited has been approved by CSRC to conduct the securities investment consultancy business. **Dubai International Financial Centre (DIFC):** JPMorgan Chase Bank, N.A., Dubai Branch is regulated by the Dubai Financial Services Authority (DFSA) and its registered address is Dubai International Financial Centre - The Gate, West Wing, Level 3 and 9 PO Box 506551, Dubai, UAE. This material has been distributed by JP Morgan Chase Bank, N.A., Dubai Branch to persons regarded as professional clients or market counterparties as defined under the DFSA rules. **European Economic Area (EEA):** Unless specified to the contrary, research is distributed in the EEA by J.P. Morgan SE (“JPM SE”), which is authorised as a credit institution by the Federal Financial Supervisory Authority (Bundesanstalt für Finanzdienstleistungsaufsicht, BaFin) and jointly supervised by the BaFin, the German Central Bank (Deutsche Bundesbank) and the European Central Bank (ECB). JPM SE is a company headquartered in Frankfurt with registered address at TaunusTurm, Taunustor 1, Frankfurt am Main, 60310, Germany. The material has been distributed in the EEA to persons regarded as professional investors (or equivalent) pursuant to Art. 4 para. 1 no. 10 and Annex II of MiFID II and its respective implementation in their home jurisdictions (“EEA professional investors”). This material must not be acted on or relied on by persons who are not EEA professional investors. Any investment or investment activity to which this material relates is only available to EEA relevant persons and will be engaged in only with EEA relevant persons. **Hong Kong:** J.P. Morgan Securities (Asia Pacific) Limited (CE number AAJ321) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission in Hong Kong, and J.P. Morgan Broking (Hong Kong) Limited (CE number AAB027) is regulated by the Securities and Futures Commission in Hong Kong. JP Morgan Chase Bank, N.A., Hong Kong Branch (CE Number AAL996) is regulated by the Hong Kong Monetary Authority and the Securities and Futures Commission, is organized under the laws of the United States with limited liability. Where the distribution of this material is a regulated activity in Hong Kong, the material is distributed in Hong Kong by or through J.P. Morgan Securities (Asia Pacific) Limited and/or J.P. Morgan Broking (Hong Kong) Limited. **India:** J.P. Morgan India Private Limited (Corporate Identity Number - U67120MH1992FTC068724), having its registered office at J.P. Morgan Tower, Off. C.S.T. Road, Kalina, Santacruz - East, Mumbai – 400098, is registered with the Securities and Exchange Board of India (SEBI) as a ‘Research Analyst’ having registration number INH000001873. J.P. Morgan India Private Limited is also registered with SEBI as a member of the National Stock Exchange of India Limited and the Bombay Stock Exchange Limited (SEBI Registration Number – INZ000239730) and as a Merchant Banker (SEBI Registration Number - MB/INM000002970). Telephone: 91-22-6157 3000, Facsimile: 91-22-6157 3990 and Website: <http://www.jpmipl.com>. JPMorgan Chase Bank, N.A. - Mumbai Branch is licensed by the Reserve Bank of India (RBI) (Licence No. 53/ Licence No. BY.4/94; SEBI - IN/CUS/014/ CDSL : IN-DP-CDSL-444-2008/ IN-DP-NSDL-285-2008/ INBI00000984/ INE231311239) as a Scheduled Commercial Bank in India, which is its primary license allowing it to carry on Banking business in India and other activities, which a Bank branch in India are permitted to undertake. For non-local research material, this material is not distributed in India by J.P. Morgan India Private Limited. Compliance Officer: Spurthi Gadamsetty; spurthi.gadamsetty@jpmchase.com; +912261573225. Grievance Officer: Ramprasad K, jpmipl.research.feedback@jpmorgan.com; +912261573000. Registration granted by SEBI and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors. **Indonesia:** PT J.P. Morgan Sekuritas Indonesia is a member of the Indonesia Stock Exchange and is registered and supervised by the Otoritas Jasa Keuangan (OJK). **Korea:** J.P. Morgan Securities (Far East) Limited, Seoul Branch, is a member of the Korea Exchange (KRX). JPMorgan Chase Bank, N.A., Seoul Branch, is licensed as a branch office of foreign bank (JPMorgan Chase Bank, N.A.) in Korea. Both entities are regulated by the Financial Services Commission (FSC) and the Financial Supervisory Service (FSS). For non-macro research material, the material is distributed in Korea by or through J.P. Morgan Securities (Far East) Limited, Seoul Branch. **Japan:** JPMorgan Securities Japan Co., Ltd. and JPMorgan Chase Bank, N.A., Tokyo Branch are regulated by the Financial Services Agency in Japan. **Malaysia:** This material is issued and distributed in Malaysia by JPMorgan Securities (Malaysia) Sdn Bhd (18146-X), which is a Participating Organization of Bursa Malaysia Berhad and holds a Capital Markets Services License issued by the Securities Commission in Malaysia. **Mexico:** J.P. Morgan Casa de Bolsa, S.A. de C.V. and J.P. Morgan Grupo Financiero are members of the Mexican Stock Exchange and are authorized to act as a broker dealer by the National Banking and Securities Exchange Commission. **New Zealand:** This material is issued and distributed by JPMSAL in New Zealand only to “wholesale clients” (as defined in the Financial Markets Conduct Act 2013). JPMSAL is registered as a Financial Service Provider under the Financial Service providers (Registration and Dispute Resolution) Act of 2008. **Philippines:** J.P. Morgan Securities Philippines Inc. is a Trading Participant of the Philippine Stock Exchange and a member of the Securities Clearing Corporation of the Philippines and the Securities Investor Protection Fund. It is regulated by the Securities and Exchange Commission. **Singapore:** This material is issued and distributed in Singapore by or through J.P. Morgan Securities Singapore Private Limited (JPMSS) [MDDI (P) 068/08/2024 and Co. Reg. No.: 199405335R], which is a member of the Singapore Exchange Securities Trading Limited, and/or JPMorgan Chase Bank, N.A., Singapore branch (JPMCB Singapore),

both of which are regulated by the Monetary Authority of Singapore. This material is issued and distributed in Singapore only to accredited investors, expert investors and institutional investors, as defined in Section 4A of the Securities and Futures Act, Cap. 289 (SFA). This material is not intended to be issued or distributed to any retail investors or any other investors that do not fall into the classes of “accredited investors,” “expert investors” or “institutional investors,” as defined under Section 4A of the SFA. Recipients of this material in Singapore are to contact JPMSS or JPMCB Singapore in respect of any matters arising from, or in connection with, the material. **South Africa:** J.P. Morgan Equities South Africa Proprietary Limited and JPMorgan Chase Bank, N.A., Johannesburg Branch are members of the Johannesburg Securities Exchange and are regulated by the Financial Services Conduct Authority (FSCA). **Taiwan:** J.P. Morgan Securities (Taiwan) Limited is a participant of the Taiwan Stock Exchange (company-type) and regulated by the Taiwan Securities and Futures Bureau. Material relating to equity securities is issued and distributed in Taiwan by J.P. Morgan Securities (Taiwan) Limited, subject to the license scope and the applicable laws and the regulations in Taiwan. According to Paragraph 2, Article 7-1 of Operational Regulations Governing Securities Firms Recommending Trades in Securities to Customers (as amended or supplemented) and/or other applicable laws or regulations, please note that the recipient of this material is not permitted to engage in any activities in connection with the material that may give rise to conflicts of interests, unless otherwise disclosed in the “Important Disclosures” in this material. **Thailand:** This material is issued and distributed in Thailand by JPMorgan Securities (Thailand) Ltd., which is a member of the Stock Exchange of Thailand and is regulated by the Ministry of Finance and the Securities and Exchange Commission, and its registered address is 3rd Floor, 20 North Sathorn Road, Silom, Bangkok, Bangkok 10500. **UK:** Unless specified to the contrary, research is distributed in the UK by J.P. Morgan Securities plc (“JPMS plc”) which is a member of the London Stock Exchange and is authorised by the Prudential Regulation Authority and regulated by the Financial Conduct Authority and the Prudential Regulation Authority. JPMS plc is registered in England & Wales No. 2711006, Registered Office 25 Bank Street, London, E14 5JP. This material is directed in the UK only to: (a) persons having professional experience in matters relating to investments falling within article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) (Order) 2005 (“the FPO”); (b) persons outlined in article 49 of the FPO (high net worth companies, unincorporated associations or partnerships, the trustees of high value trusts, etc.); or (c) any persons to whom this communication may otherwise lawfully be made; all such persons being referred to as “UK relevant persons”. This material must not be acted on or relied on by persons who are not UK relevant persons. Any investment or investment activity to which this material relates is only available to UK relevant persons and will be engaged in only with UK relevant persons. Research issued by JPMS plc has been prepared in accordance with JPMS plc's policy for prevention and avoidance of conflicts of interest related to the production of Research which can be found at the following link: [J.P. Morgan EMEA - Research Independence Policy](#). **U.S.:** J.P. Morgan Securities LLC (“JPMS”) is a member of the NYSE, FINRA, SIPC, and the NFA. JPMorgan Chase Bank, N.A. is a member of the FDIC. Material published by non-U.S. affiliates is distributed in the U.S. by JPMS who accepts responsibility for its content.

General: Additional information is available upon request. The information in this material has been obtained from sources believed to be reliable. While all reasonable care has been taken to ensure that the facts stated in this material are accurate and that the forecasts, opinions and expectations contained herein are fair and reasonable, JPMorgan Chase & Co. or its affiliates and/or subsidiaries (collectively J.P. Morgan) make no representations or warranties whatsoever to the completeness or accuracy of the material provided, except with respect to any disclosures relative to J.P. Morgan and the Research Analyst's involvement with the issuer that is the subject of the material. Accordingly, no reliance should be placed on the accuracy, fairness or completeness of the information contained in this material. There may be certain discrepancies with data and/or limited content in this material as a result of calculations, adjustments, translations to different languages, and/or local regulatory restrictions, as applicable. These discrepancies should not impact the overall investment analysis, views and/or recommendations of the subject company(ies) that may be discussed in the material. J.P. Morgan accepts no liability whatsoever for any loss arising from any use of this material or its contents, and neither J.P. Morgan nor any of its respective directors, officers or employees, shall be in any way responsible for the contents hereof, apart from the liabilities and responsibilities that may be imposed on them by the relevant regulatory authority in the jurisdiction in question, or the regulatory regime thereunder. Opinions, forecasts or projections contained in this material represent J.P. Morgan's current opinions or judgment as of the date of the material only and are therefore subject to change without notice. Periodic updates may be provided on companies/industries based on company-specific developments or announcements, market conditions or any other publicly available information. There can be no assurance that future results or events will be consistent with any such opinions, forecasts or projections, which represent only one possible outcome. Furthermore, such opinions, forecasts or projections are subject to certain risks, uncertainties and assumptions that have not been verified, and future actual results or events could differ materially. The value of, or income from, any investments referred to in this material may fluctuate and/or be affected by changes in exchange rates. All pricing is indicative as of the close of market for the securities discussed, unless otherwise stated. Past performance is not indicative of future results. Accordingly, investors may receive back less than originally invested. This material is not intended as an offer or solicitation for the purchase or sale of any financial instrument. The opinions and recommendations herein do not take into account individual client circumstances, objectives, or needs and are not intended as recommendations of particular securities, financial instruments or strategies to particular clients. This material may include views on structured securities, options, futures and other derivatives. These are complex instruments, may involve a high degree of risk and may be appropriate investments only for sophisticated investors who are capable of understanding and assuming the risks involved. The recipients of this material must make their own independent decisions regarding any securities or financial instruments mentioned herein and should seek advice from such independent financial, legal, tax or other adviser as they deem necessary. J.P. Morgan may trade as a principal on the basis of the Research Analysts' views and research, and it may also engage in transactions for its own account or for its clients' accounts in a manner inconsistent with the views taken in this material, and J.P. Morgan is under no obligation to ensure that such other communication is brought to the attention of any recipient of this material. Others within J.P. Morgan, including Strategists, Sales staff and other Research Analysts, may take views that are inconsistent with those taken in this material. Employees of J.P. Morgan not involved in the preparation of this material may have investments in the securities (or derivatives of such securities) mentioned in this material and may trade them in ways different from those discussed in this material. This material is not an advertisement for or marketing of any issuer, its products or services, or its securities in any jurisdiction.

Confidentiality and Security Notice: This transmission may contain information that is privileged, confidential, legally privileged, and/or exempt from disclosure under applicable law. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution, or use of the information contained herein (including any reliance thereon) is STRICTLY PROHIBITED. Although this transmission and any attachments are believed to be free of any virus or other defect that might affect any computer system into which it is received and opened, it is the responsibility of the recipient to ensure that it is virus free and no responsibility is accepted by JPMorgan Chase & Co., its subsidiaries and affiliates, as applicable, for any loss or damage arising in any way from its use. If you received this transmission in error, please immediately contact the sender and destroy the material in its entirety, whether in electronic or hard copy format. This message is subject to electronic monitoring: <https://www.jpmorgan.com/disclosures/email>

MSCI: Certain information herein (“Information”) is reproduced by permission of MSCI Inc., its affiliates and information providers (“MSCI”) ©2025. No reproduction or dissemination of the Information is permitted without an appropriate license. MSCI MAKES NO EXPRESS OR IMPLIED WARRANTIES (INCLUDING MERCHANTABILITY OR FITNESS) AS TO THE INFORMATION AND DISCLAIMS ALL LIABILITY TO THE EXTENT PERMITTED BY LAW. No Information constitutes investment advice, except for any applicable Information from MSCI ESG Research. Subject also to msci.com/disclaimer

Sustainalytics: Certain information, data, analyses and opinions contained herein are reproduced by permission of Sustainalytics and: (1) includes the proprietary information of Sustainalytics; (2) may not be copied or redistributed except as specifically authorized; (3) do not constitute investment advice nor an endorsement of any product or project; (4) are provided solely for informational purposes; and (5) are not warranted to be complete, accurate or timely. Sustainalytics is not responsible for any trading decisions, damages or other losses related to it or its use. The use of the data is subject to conditions available at <https://www.sustainalytics.com/legal-disclaimers>. ©2025 Sustainalytics. All Rights Reserved.

"Other Disclosures" last revised January 01, 2025.

Copyright 2025 JPMorgan Chase & Co. All rights reserved. This material or any portion hereof may not be reprinted, sold or redistributed without the written consent of J.P. Morgan. It is strictly prohibited to use or share without prior written consent from J.P. Morgan any research material received from J.P. Morgan or an authorized third-party (“J.P. Morgan Data”) in any third-party artificial intelligence (“AI”) systems or models when such J.P. Morgan Data is accessible by a third-party. It is permissible to use J.P. Morgan Data for internal business purposes only in an AI system or model that protects the confidentiality of J.P. Morgan Data so as to prevent any and all access to or use of such J.P. Morgan Data by any third-party.

Completed 10 Feb 2025 09:06 PM EST

Disseminated 10 Feb 2025 09:06 PM EST